Voyager Therapeutics (VYGR) Capital Expenditures (2014 - 2026)
Voyager Therapeutics (VYGR) reported Capital Expenditures of $14000.0 for Q1 2026, down 97.87% on a YoY basis from $658000.0 in Q1 2025, and up 100.91% sequentially from -$1.5 million in Q4 2025.
Voyager Therapeutics (VYGR) Capital Expenditures (2014 - 2026) Analysis & Trends
Voyager Therapeutics (VYGR) has 13 years of Capital Expenditures data on file, last reported at $14000.0 in Q1 2026.
- For the quarter ending Q1 2026, Capital Expenditures fell 97.87% year-over-year to $14000.0; the trailing twelve-month figure through Mar 2026 stood at -$217000.0 (down 105.21% YoY), and the FY2025 full-year result was $427000.0, down 87.87% from the prior year.
- Capital Expenditures grew to $14000.0 in Q1 2026, from -$1.5 million in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $3.1 million in Q2 2024 to a low of -$1.5 million in Q4 2025.
- A 5-year average of $571117.6 and a median of $258000.0 in 2024 frame the typical range for Capital Expenditures.
- Peak annual rise in Capital Expenditures reached 4286.67% in 2025, while the deepest fall reached 1095.48% in 2025.
- Tracing VYGR's Capital Expenditures over 5 years: stood at $933000.0 in 2022, then decreased by 19.08% to $755000.0 in 2023, then slumped by 79.47% to $155000.0 in 2024, then sank by 1095.48% to -$1.5 million in 2025, then surged by 100.91% to $14000.0 in 2026.
- Business Quant data shows VYGR's Capital Expenditures at $14000.0 in Q1 2026, -$1.5 million in Q4 2025, and $207000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Voyager Therapeutics | 183.84 Mn | 42.36 Mn | - | 14,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14,000.00 |
| Mar 31, 2026 | 14,000.00 |
| Dec 31, 2025 | -1.54 Mn |
| Dec 31, 2025 | -1.54 Mn |
| Sep 30, 2025 | 207,000.00 |
| Sep 30, 2025 | 207,000.00 |
| Jun 30, 2025 | 1.11 Mn |
| Jun 30, 2025 | 1.11 Mn |
| Mar 31, 2025 | 658,000.00 |
| Mar 31, 2025 | 658,000.00 |
| Dec 31, 2024 | 155,000.00 |
| Dec 31, 2024 | 155,000.00 |
| Sep 30, 2024 | 258,000.00 |
| Sep 30, 2024 | 258,000.00 |
| Jun 30, 2024 | 3.09 Mn |
| Jun 30, 2024 | 3.09 Mn |
| Mar 31, 2024 | 15,000.00 |
| Mar 31, 2024 | 15,000.00 |
| Dec 31, 2023 | 755,000.00 |
| Dec 31, 2023 | 755,000.00 |